buy near launch-readi sacituzuab
eye pdufa ascent trial pipelin expand
messag report result provid corpor updat management
remain confid outcom re-submit sacituzumab govitecan bla
request acceler approv metastat tripl neg breast cancer mtnbc
potenti disclosur top-lin result confirmatori ascent phase trial remain
track launch readi activ well underway us
provid visibl potenti label extens opportun sacituzumab
includ bladder breast lung cancer updat estim maintain
management remain confid address outstand issu
sacituzumab bla launch readi pdufa date june
management disclos mani detail progress re-inspect appear
confid view management note commun well agenc two
type-a meet believ success address outstand issu
recal recent resubmit biolog licens applic bla sacituzumab
govitecan sg link seek acceler approv sacituzumab govitecan
treatment patient metastat triple-neg breast cancer mtnbc
receiv least two prior therapi metastat diseas previous januari link
announc receiv complet respons letter
food drug administr fda biolog licens applic bla issu
relat approv exclus focus chemistri manufactur
control matter new clinic preclin data need accord
phase ascent top-lin result continu guid management note
requir number event reach trigger final analysi
expect occur near term continu guid top-lin result
remain investor debat whether result ascent trial may requir
fda come approv decis manag reiter prior remark
issu rais exclus relat clinic data manag
remain highli confid potenti posit ascent outcom given sacituzumab phase
ii data show signific improv orr mpf month
compar favor histor proxi control arm trial orr
month mpf posit ascent trial result could also read-through posit
on-going similar design larger market
pivot bladder cancer guid read-out new
cohort evalu sg keytruda ad first cohort complet
enrol cisplatin-elig patient report initi result interim
analysi patient esmo congress see field report guid today
final analysi support acceler approv expect approv sg
would second set follow recent approv sgen padcev
second cohort test sg front-lin treatment cisplatin-inelig bladder cancer
patient expect complet enrol also announc addit
new cohort evalu sg combin keytruda bladder cancer patient
progress front-lin chemotherapi
phase phase trial complet patient enrol trial
evalu sacituzumab patient tnbc popul size similar
design phase ascent management note trial could complet patient enrol
end interim analysi orr could potenti support acceler approv
tumor-agnost trial report preliminari data lung cancer patient
sacituzumab histor demonstr orr nsclc patient regardless
page analyst certif import disclosur
express level warrant develop singl agent
all-com set accord evalu sacituzumab
patient elev express level start nsclc plan expand
tumor type pend posit signal preliminari result nsclc patient
guid
financi sg expens respect
expens in-lin estim consensu primarili due
clinic trial manufactur relat activ compani cash
equival end receiv mileston patient everest
medicin pend potenti approv sg year maintain buy rate given
signific unmet need mtnbc bullish view kol sg
tnbc link upsid market potenti cancer type expect
upcom decis fda key binari event updat model
reflect financi pt remain
page analyst certif import disclosur
valuat risk
valu per share use dcf base valuat method slightli
chang near term expens forecast base financi result valuat includ lead
product candid sacituzumab govitecan patient tnbc muc breast cancer
use discount rate consist commerci stage biotech compani
coverag termin growth rate appli termin year post-assum
sacituzumab biosimilar entri
risk valuat includ regulatori commerci setback potenti
emerg new competitor /or lower product sale expect risk
intellectu properti risk manag execut misstep
page analyst certif import disclosur
total cost expens
total expens incom
guggenheim secur llc estim sec file
page analyst certif import disclosur
licens fee revenu
research develop
total expens incom
net incom tax
net loss attribut non-controlling interest
guggenheim secur llc estim sec file
page analyst certif import disclosur
